BRPI0408442A - método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato - Google Patents
método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioatoInfo
- Publication number
- BRPI0408442A BRPI0408442A BRPI0408442-0A BRPI0408442A BRPI0408442A BR PI0408442 A BRPI0408442 A BR PI0408442A BR PI0408442 A BRPI0408442 A BR PI0408442A BR PI0408442 A BRPI0408442 A BR PI0408442A
- Authority
- BR
- Brazil
- Prior art keywords
- phenyl
- amino
- methylpropanothioate
- ethylbutyl
- increasing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
"MéTODO PARA AUMENTO DA BIODISPONIBILIDADE ORAL DE S-¢2-(¢¢1-(2-ETILBUTIL)CICLOHEXIL!CARBONIL!AMINO)FENIL!2- METILPROPANOTIOATO". A presente invenção refere-se a um método de aumento da biodisponibilidade da forma ativa de S-¢2-(¢¢1-(2-etilbutil)ciclohexil!carbonil!amino)fenil!2-metilpropanotioat o através da administração de uma quantidade terapeuticamente eficaz da droga com alimento. A invenção também provê um kit compreendendo uma composição farmacêutica compreendendo uma quantidade terapeuticamente eficaz de S-¢2-(¢¢1-(2-etilbutil)ciclohexil!carbonil!amino)fenil!2-metilpropanotioat o e um veículo farmaceuticamente aceitável, informação de prescrição e um recipiente, onde a informação de prescrição inclui aviso a um paciente com relação à administração da droga com alimento para melhorar a biodisponibilidade.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45529303P | 2003-03-17 | 2003-03-17 | |
US46052103P | 2003-04-04 | 2003-04-04 | |
US47720203P | 2003-06-10 | 2003-06-10 | |
PCT/JP2004/003589 WO2004082675A1 (en) | 2003-03-17 | 2004-03-17 | Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0408442A true BRPI0408442A (pt) | 2006-04-04 |
Family
ID=33033150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0408442-0A BRPI0408442A (pt) | 2003-03-17 | 2004-03-17 | método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato |
Country Status (11)
Country | Link |
---|---|
US (2) | US7276536B2 (pt) |
EP (1) | EP1603554A1 (pt) |
JP (1) | JP2006520810A (pt) |
KR (1) | KR20050110017A (pt) |
AU (1) | AU2004222436A1 (pt) |
BR (1) | BRPI0408442A (pt) |
CA (1) | CA2519458A1 (pt) |
CO (1) | CO5700729A2 (pt) |
MX (1) | MXPA05009976A (pt) |
NO (1) | NO20054739L (pt) |
WO (1) | WO2004082675A1 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
JP2006520810A (ja) * | 2003-03-17 | 2006-09-14 | 日本たばこ産業株式会社 | S−[2−([[1−(2−エチルブチル)シクロヘキシル]カルボニル]アミノ)フェニル]2−メチルプロパンチオエートの経口吸収性を増加させる方法 |
TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
CA2687118A1 (en) | 2006-05-19 | 2007-12-13 | Somaxon Pharmaceuticals, Inc. | Methods of using low-dose doxepin for the improvement of sleep |
US20080058408A1 (en) | 2006-05-19 | 2008-03-06 | Rogowski Roberta L | Low-dose doxepin for treatment of sleep disorders in elderly patients |
US20100179214A1 (en) | 2006-05-19 | 2010-07-15 | Somaxon Pharmaceuticals, Inc. | Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders |
US20100227916A1 (en) * | 2006-05-19 | 2010-09-09 | Somaxon Pharmaceuticals, Inc | N-desmethyl-doxepin and methods of using the same to treat sleep disorders |
US20100179215A1 (en) | 2006-05-19 | 2010-07-15 | Somaxon Pharmaceuticals, Inc. | Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders |
WO2008011150A1 (en) * | 2006-07-20 | 2008-01-24 | Somaxon Pharmaceuticals, Inc. | Methods of improving the pharmacokinetics of doxepin |
WO2008085567A1 (en) * | 2006-10-04 | 2008-07-17 | Somaxon Pharmaceuticals, Inc. | Methods of using low-dose doxepin for the improvement of sleep |
US20100105614A1 (en) | 2006-10-25 | 2010-04-29 | Somaxon Pharmaceuticals, Inc. | Ultra low dose doxepin and methods of using the same to treat sleep disorders |
WO2008070795A2 (en) | 2006-12-06 | 2008-06-12 | Somaxon Pharmaceuticals, Inc. | Combination therapy using low-dose doxepin for the improvement of sleep |
WO2008128115A2 (en) | 2007-04-13 | 2008-10-23 | Somaxon Pharmaceuticals, Inc. | Low-dose doxepin formulations |
WO2010066593A1 (en) * | 2008-12-08 | 2010-06-17 | F. Hoffmann-La Roche Ag | Combined drug administration |
WO2012059447A1 (en) | 2010-11-04 | 2012-05-10 | F. Hoffmann-La Roche Ag | A composition comprising s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and croscarmellose sodium |
PT2978859T (pt) | 2013-03-27 | 2018-10-04 | Hoffmann La Roche | Marcadores genéticos para previsão da capacidade de resposta à terapêutica |
MX2017000582A (es) | 2014-07-30 | 2017-04-27 | Hoffmann La Roche | Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl). |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3576830A (en) * | 1966-08-12 | 1971-04-27 | Sumitomo Chemical Co | Amides containing sulfur |
JPS4735786U (pt) | 1971-05-10 | 1972-12-20 | ||
US4346277A (en) * | 1979-10-29 | 1982-08-24 | Eaton Corporation | Packaged electrical heating element |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US4940727A (en) * | 1986-06-23 | 1990-07-10 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
USRE36481E (en) * | 1986-06-23 | 2000-01-04 | Merck & Co., Inc. | HMG-CoA reductase inhibitors |
US4740438A (en) * | 1986-12-10 | 1988-04-26 | Eastman Kodak Company | Organic disulfides as image dye stabilizers |
US4853319A (en) * | 1986-12-22 | 1989-08-01 | Eastman Kodak Company | Photographic silver halide element and process |
JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
US5180589A (en) * | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
JPH01278543A (ja) | 1988-04-30 | 1989-11-08 | Sanshin Chem Ind Co Ltd | ゴム組成物 |
JPH01321432A (ja) | 1988-06-22 | 1989-12-27 | Konica Corp | ハロゲン化銀写真感光材料 |
JPH0223338A (ja) | 1988-07-12 | 1990-01-25 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
US5118583A (en) * | 1988-10-12 | 1992-06-02 | Mitsubishi Paper Mills Limited | Processing composition for printing plate |
DE3835198A1 (de) | 1988-10-15 | 1990-04-19 | Bayer Ag | Verfahren zur herstellung von kautschukvulkanisaten mit verringerten hystereseverlusten und formkoerper aus diesen vulkanisaten |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
JPH03226750A (ja) | 1990-01-31 | 1991-10-07 | Konica Corp | ハロゲン化銀カラー写真感光材料 |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
FR2665450B1 (fr) * | 1990-08-01 | 1994-04-08 | Rhone Poulenc Chimie | Procede de preparation de dispersions aqueuses de copolymeres. |
GB9017710D0 (en) | 1990-08-13 | 1990-09-26 | May & Baker Ltd | New compositions of matter |
GB9017711D0 (en) | 1990-08-13 | 1990-09-26 | May & Baker Ltd | New compositions of matter |
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
GB9120131D0 (en) | 1991-09-20 | 1991-11-06 | Glaxo Group Ltd | Medicaments |
HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
WO1993011782A1 (en) * | 1991-12-19 | 1993-06-24 | Southwest Foundation For Biomedical Research | Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
US5519001A (en) * | 1991-12-19 | 1996-05-21 | Southwest Foundation For Biomedical Research | CETP inhibitor polypeptide antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
US5217859A (en) * | 1992-04-16 | 1993-06-08 | Eastman Kodak Company | Aqueous, solid particle dispersions of dichalcogenides for photographic emulsions and coatings |
US5219721A (en) * | 1992-04-16 | 1993-06-15 | Eastman Kodak Company | Silver halide photographic emulsions sensitized in the presence of organic dichalcogenides |
ATE178794T1 (de) * | 1993-01-19 | 1999-04-15 | Warner Lambert Co | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
US5350667A (en) * | 1993-06-17 | 1994-09-27 | Eastman Kodak Company | Photographic elements containing magenta couplers and process for using same |
US5534529A (en) * | 1993-06-30 | 1996-07-09 | Sankyo Company, Limited | Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses |
IL110159A0 (en) * | 1993-06-30 | 1994-10-07 | Wellcome Found | Diaryl compounds, their preparation and pharmaceutical compositions containing them |
US5446207A (en) * | 1993-09-01 | 1995-08-29 | Harbor Branch Oceanographic Institution, Inc. | Anti-dyslipidemic agents |
US5459154A (en) * | 1993-11-08 | 1995-10-17 | American Home Products Corporation | N-hydroxyureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low density lipoprotein |
US5405969A (en) * | 1993-12-10 | 1995-04-11 | Eastman Kodak Company | Manufacture of thioether compounds |
JP3304189B2 (ja) * | 1994-03-18 | 2002-07-22 | マツダ株式会社 | 加硫スクラップゴムを含有する成形用ゴム組成物及びその製造方法 |
US5654134A (en) * | 1994-05-18 | 1997-08-05 | Fuji Photo Film Co., Ltd. | Silver halide emulsion |
DE4428457C1 (de) * | 1994-08-11 | 1995-10-05 | Bayer Ag | Geformte, paraffinhaltige Mastiziermittel |
US6001555A (en) | 1994-09-23 | 1999-12-14 | The United States Of America As Represented By The Department Of Health And Human Services | Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein |
JPH09501186A (ja) * | 1994-11-12 | 1997-02-04 | 株式会社エルジ化学 | コレステリルエステル運搬蛋白質阻害ペプチドおよびこれを含む動脈硬化症のための予防および治療剤 |
DE69520345T2 (de) * | 1994-12-26 | 2001-09-06 | Nisshin Flour Milling Co | Diphenyl-disulfid Verbindungen |
AU4770296A (en) | 1995-03-27 | 1996-10-16 | Warner-Lambert Company | Method and apparatus for simultaneously testing a plurality of compounds to detect their activity |
BR9609872A (pt) * | 1995-07-17 | 1999-03-23 | Warner Lambert Co | Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino |
JPH0959155A (ja) | 1995-08-23 | 1997-03-04 | Kaken Pharmaceut Co Ltd | コレステリルエステル転送反応阻害剤 |
DE19610932A1 (de) * | 1996-03-20 | 1997-09-25 | Bayer Ag | 2-Aryl-substituierte Pyridine |
US6207671B1 (en) * | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
DE19627431A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
ES2127690B1 (es) | 1996-08-02 | 2000-01-01 | Univ Granada | Procedimientos de obtencion de (+)-puupehenona a partir de terpenoides biciclicos. |
YU23499A (sh) | 1996-11-27 | 2001-07-10 | Pfizer Inc. | Inhibitorski amidi apo-b-sekrecije/mtp-a |
DE19704243A1 (de) | 1997-02-05 | 1998-08-06 | Bayer Ag | Neue 2-Amino-substituierte Pyridine |
JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Cetp活性阻害剤として有効な化合物 |
DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
JPH10287662A (ja) | 1997-04-08 | 1998-10-27 | Kitasato Inst:The | Fo−5637a物質及びb物質並びにそれらの製造法 |
US6093573A (en) * | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
AU9297798A (en) | 1997-09-16 | 1999-04-05 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
US5916595A (en) * | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
AU3285499A (en) | 1998-02-13 | 1999-08-30 | G.D. Searle & Co. | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
US6692909B1 (en) | 1998-04-01 | 2004-02-17 | Whitehead Institute For Biomedical Research | Coding sequence polymorphisms in vascular pathology genes |
US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
ATE296796T1 (de) | 1998-09-25 | 2005-06-15 | Monsanto Co | (r)-chirale halogenierte 1-substituierte amino- (n+1)-alkanolen für die hemmung der aktivität des cholesteryl-ester-transfer-proteins |
CA2345108A1 (en) | 1998-09-25 | 2000-04-06 | Monsanto Company | Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
PT1140185E (pt) | 1998-12-23 | 2003-10-31 | Searle Llc | Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com agentes sequestrantes de acido biliar para indicacoes cardiovasculares |
WO2000038722A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS |
NZ512534A (en) | 1998-12-23 | 2003-11-28 | G | Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications |
EP1140184B1 (en) | 1998-12-23 | 2003-06-04 | G.D. Searle LLC. | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
US20010018446A1 (en) * | 1999-09-23 | 2001-08-30 | G.D. Searle & Co. | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
US6451830B1 (en) * | 1999-09-23 | 2002-09-17 | G.D. Searle & Co. | Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity |
HN2000000203A (es) * | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
IL158765A0 (en) * | 2001-06-21 | 2004-05-12 | Pfizer Prod Inc | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
JP2006520810A (ja) * | 2003-03-17 | 2006-09-14 | 日本たばこ産業株式会社 | S−[2−([[1−(2−エチルブチル)シクロヘキシル]カルボニル]アミノ)フェニル]2−メチルプロパンチオエートの経口吸収性を増加させる方法 |
ES2377121T3 (es) * | 2003-03-17 | 2012-03-22 | Japan Tobacco Inc. | Composiciones farmacéuticas de inhibidores de CETP |
TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
-
2004
- 2004-03-17 JP JP2006507671A patent/JP2006520810A/ja not_active Withdrawn
- 2004-03-17 US US10/802,280 patent/US7276536B2/en active Active
- 2004-03-17 KR KR1020057017446A patent/KR20050110017A/ko not_active Application Discontinuation
- 2004-03-17 EP EP04721354A patent/EP1603554A1/en not_active Withdrawn
- 2004-03-17 MX MXPA05009976A patent/MXPA05009976A/es not_active Application Discontinuation
- 2004-03-17 CA CA002519458A patent/CA2519458A1/en not_active Abandoned
- 2004-03-17 BR BRPI0408442-0A patent/BRPI0408442A/pt not_active IP Right Cessation
- 2004-03-17 WO PCT/JP2004/003589 patent/WO2004082675A1/en not_active Application Discontinuation
- 2004-03-17 AU AU2004222436A patent/AU2004222436A1/en not_active Abandoned
-
2005
- 2005-10-14 NO NO20054739A patent/NO20054739L/no not_active Application Discontinuation
- 2005-10-14 CO CO05105280A patent/CO5700729A2/es not_active Application Discontinuation
-
2007
- 2007-08-29 US US11/847,085 patent/US20080045599A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20054739D0 (no) | 2005-10-14 |
EP1603554A1 (en) | 2005-12-14 |
NO20054739L (no) | 2005-12-14 |
WO2004082675A8 (en) | 2005-11-03 |
KR20050110017A (ko) | 2005-11-22 |
CO5700729A2 (es) | 2006-11-30 |
CA2519458A1 (en) | 2004-09-30 |
US7276536B2 (en) | 2007-10-02 |
JP2006520810A (ja) | 2006-09-14 |
AU2004222436A1 (en) | 2004-09-30 |
US20040242683A1 (en) | 2004-12-02 |
WO2004082675A1 (en) | 2004-09-30 |
MXPA05009976A (es) | 2005-11-04 |
US20080045599A1 (en) | 2008-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0408442A (pt) | método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato | |
KR102424765B1 (ko) | 외상후 스트레스 장애의 치료 방법 | |
ATE420632T1 (de) | Titrationsdosierschema für kontrolliert freigesetztes tramadol | |
BRPI0406486A (pt) | Dispositivo de administração para medicamento fluido | |
ATE306266T1 (de) | Verbesserte verabreichungstechnik für multiple medikamentengaben | |
BRPI0406883A (pt) | Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
BR0207883A (pt) | Composições de medicamentos à base de anticolenérgicos e inibidores de pde-iv | |
DE60330322D1 (de) | Arzneimittel-mikroteilchen | |
BR0010498A (pt) | Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos | |
IL183309A0 (en) | Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide | |
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
BR0107564A (pt) | Composição de gliburida | |
AU2003243439A1 (en) | Medical device for intra-lumenal delivery of pharmaceutical agents | |
MXPA05012358A (es) | Combinacion farmaceutica que comprende modafinilo y otra droga. | |
BRPI0412364A (pt) | composição farmacêutica sólida, compreendendo amisulpride | |
DE60208180D1 (de) | Modifiziertes, als medikamentvorstufe anwendbares cyclosporin und dessen verwendung | |
US20230404947A1 (en) | Compositions, methods of treatment, and containers including compositions | |
HUP0204391A2 (en) | The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders | |
US20210361598A1 (en) | Compounds for prevention and treatment of post-intensive care cognitive dysfunction and cognitive dysfunction resulting from respiratory distress | |
AR039162A1 (es) | Formulaciones de venlafaxina de liberacion extendida | |
JP2023546294A (ja) | Gp130シグナル伝達経路の小分子モジュレーター、局所製剤およびその使用方法 | |
AU2003257589A1 (en) | Remedy for integration dysfunction syndrome | |
ATE446759T1 (de) | Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden | |
ZA200600165B (en) | Amino acid diamides in non alpha position useful as adjuvants for the administration of active biological agents | |
JP7250698B2 (ja) | 中枢神経系の変性疾患及び/又はリソソーム蓄積疾患を予防及び/又は治療するための新規組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |